1
|
Domínguez-Jurado E, Ripoll C, Lara-Sánchez A, Ocaña A, Vitórica-Yrezábal IJ, Bravo I, Alonso-Moreno C. Evaluation of heteroscorpionate ligands as scaffolds for the generation of Ruthenium(II) metallodrugs in breast cancer therapy. J Inorg Biochem 2024; 253:112486. [PMID: 38266323 DOI: 10.1016/j.jinorgbio.2024.112486] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2023] [Revised: 01/14/2024] [Accepted: 01/15/2024] [Indexed: 01/26/2024]
Abstract
The modular synthesis of the heteroscorpionate core is explored as a tool for the rapid development of ruthenium-based therapeutic agents. Starting with a series of structurally diverse alcohol-NN ligands, a family of heteroscorpionate-based ruthenium derivatives was synthesized, characterized, and evaluated as an alternative to platinum therapy for breast cancer therapy. In vitro, the antitumoral activity of the novel derivatives was assessed in a series of breast cancer cell lines using UNICAM-1 and cisplatin as metallodrug control. Through this approach, a bimetallic heteroscorpionate-based metallodrug (RUSCO-2) was identified as the lead compound of the series with an IC50 value range as low as 3-5 μM. Notably, RUSCO-2 was found to be highly cytotoxic in TNBC cell lines, suggesting a mode of action independent of the receptor status of the cells. As a proof of concept and taking advantage of the luminescent properties of one of the complexes obtained, uptake was monitored in human breast cancer MCF7 cell lines by fluorescence lifetime imaging microscopy (FLIM) to reveal that the compound is evenly distributed in the cytoplasm and that the incorporation of the heteroscorpionate ligand protects it from aqueous processes, conversion in another entity, or the loss of the chloride group. Finally, ROS studies were conducted, lipophilicity was estimated, the chloride/water exchange was studied, and stability studies in simulated biological media were carried out to propose structure-activity relationships.
Collapse
Affiliation(s)
- Elena Domínguez-Jurado
- Universidad de Castilla-La Mancha, Unidad nanoDrug, Facultad de Farmacia de Albacete, 02008 Albacete, Spain; Universidad de Castilla-La Mancha, Departamento de Química Inorgánica, Orgánica y Bioquímica, Facultad de Ciencias y Tecnologías Químicas-Centro de Innovación en Química Avanzada (ORFEO-CINQA), Ciudad Real 13071, Spain
| | - Consuelo Ripoll
- Universidad de Castilla-La Mancha, Unidad nanoDrug, Facultad de Farmacia de Albacete, 02008 Albacete, Spain; Universidad de Castilla-La Mancha, Departamento de Química Física. Facultad de Farmacia de Albacete, Albacete 02071, Spain
| | - Agustín Lara-Sánchez
- Universidad de Castilla-La Mancha, Departamento de Química Inorgánica, Orgánica y Bioquímica, Facultad de Ciencias y Tecnologías Químicas-Centro de Innovación en Química Avanzada (ORFEO-CINQA), Ciudad Real 13071, Spain
| | - Alberto Ocaña
- Experimental Therapeutics Unit, Hospital clínico San Carlos, IdISSC and CIBERONC, Madrid, Spain
| | - Iñigo J Vitórica-Yrezábal
- Departamento de Química Inorgánica, Facultad de Ciencias, Universidad de Granada, Avda de Fuentenueva. s/n, 18071 Granada, Spain
| | - Iván Bravo
- Universidad de Castilla-La Mancha, Unidad nanoDrug, Facultad de Farmacia de Albacete, 02008 Albacete, Spain; Universidad de Castilla-La Mancha, Departamento de Química Física. Facultad de Farmacia de Albacete, Albacete 02071, Spain
| | - Carlos Alonso-Moreno
- Universidad de Castilla-La Mancha, Unidad nanoDrug, Facultad de Farmacia de Albacete, 02008 Albacete, Spain; Universidad de Castilla-La Mancha, Departamento de Química Inorgánica, Orgánica y Bioquímica, Facultad de Ciencias y Tecnologías Químicas-Centro de Innovación en Química Avanzada (ORFEO-CINQA), Ciudad Real 13071, Spain.
| |
Collapse
|
2
|
Dual functionality of novel Porous-Osmium(IV)-MOFs. J Mol Struct 2023. [DOI: 10.1016/j.molstruc.2022.134150] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
3
|
Domínguez-Jurado E, Cimas FJ, Castro-Osma JA, Juan A, Lara-Sánchez A, Rodríguez-Diéguez A, Shafir A, Ocaña A, Alonso-Moreno C. Tuning the Cytotoxicity of Bis-Phosphino-Amines Ruthenium(II) Para-Cymene Complexes for Clinical Development in Breast Cancer. Pharmaceutics 2021; 13:pharmaceutics13101559. [PMID: 34683852 PMCID: PMC8539368 DOI: 10.3390/pharmaceutics13101559] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2021] [Revised: 09/21/2021] [Accepted: 09/22/2021] [Indexed: 11/30/2022] Open
Abstract
Despite some limitations such as long-term side effects or the potential presence of intrinsic or acquired resistance, platinum compounds are key therapeutic components for the treatment of several solid tumors. To overcome these limitations, maintaining the same efficacy, organometallic ruthenium(II) compounds have been proposed as a viable alternative to platinum agents as they have a more favorable toxicity profile and represent an ideal template for both, high-throughput and rational drug design. To support the preclinical development of bis-phoshino-amine ruthenium compounds in the treatment of breast cancer, we carried out chemical modifications in the structure of these derivatives with the aim of designing less toxic and more efficient therapeutic agents. We report new bis-phoshino-amine ligands and the synthesis of their ruthenium counterparts. The novel ligands and compounds were fully characterized, water stability analyzed, and their in vitro cytotoxicity against a panel of tumor cell lines representative of different breast cancer subtypes was evaluated. The mechanism of action of the lead compound of the series was explored. In vivo toxicity was also assessed. The results obtained in this article might pave the way for the clinical development of these compounds in breast cancer therapy.
Collapse
Affiliation(s)
- Elena Domínguez-Jurado
- Centro Regional de Investigaciones Biomédicas, Unidad NanoCRIB, 02008 Albacete, Spain; (E.D.-J.); (J.A.C.-O.); (A.J.)
- Facultad de Farmacia de Albacete, Universidad de Castilla-La Mancha, 02008 Albacete, Spain
| | - Francisco J. Cimas
- Oncología Traslacional, Unidad de Investigación del Complejo Hospitalario Universitario de Albacete, 02008 Albacete, Spain;
| | - José Antonio Castro-Osma
- Centro Regional de Investigaciones Biomédicas, Unidad NanoCRIB, 02008 Albacete, Spain; (E.D.-J.); (J.A.C.-O.); (A.J.)
- Facultad de Farmacia de Albacete, Universidad de Castilla-La Mancha, 02008 Albacete, Spain
| | - Alberto Juan
- Centro Regional de Investigaciones Biomédicas, Unidad NanoCRIB, 02008 Albacete, Spain; (E.D.-J.); (J.A.C.-O.); (A.J.)
- Facultad de Farmacia de Albacete, Universidad de Castilla-La Mancha, 02008 Albacete, Spain
| | - Agustín Lara-Sánchez
- Facultad de Ciencias y Tecnologías Químicas, Universidad de Castilla-La Mancha, 13005 Ciudad Real, Spain;
| | - Antonio Rodríguez-Diéguez
- Departamento de Química Inorgánica, Facultad de Ciencias, Universidad de Granada, Avda de Fuentenueva s/n, 18071 Granada, Spain;
| | - Alexandr Shafir
- Department of Biological Chemistry, Institute of Advanced Chemistry of Catalonia, IQAC-CSIC, c/Jordi Girona 18-26, 08034 Barcelona, Spain;
| | - Alberto Ocaña
- Experimental Therapeutics Unit, Hospital Clínico San Carlos, IdISSC and CIBERONC, 28040 Madrid, Spain
- Correspondence: (A.O.); (C.A.-M.); Tel.: +34-6356-81806 (A.O.); +34-9675-99200 (C.A.-M.)
| | - Carlos Alonso-Moreno
- Centro Regional de Investigaciones Biomédicas, Unidad NanoCRIB, 02008 Albacete, Spain; (E.D.-J.); (J.A.C.-O.); (A.J.)
- Facultad de Farmacia de Albacete, Universidad de Castilla-La Mancha, 02008 Albacete, Spain
- Correspondence: (A.O.); (C.A.-M.); Tel.: +34-6356-81806 (A.O.); +34-9675-99200 (C.A.-M.)
| |
Collapse
|
4
|
Cumin Prevents 17β-Estradiol-Associated Breast Cancer in ACI Rats. Int J Mol Sci 2021; 22:ijms22126194. [PMID: 34201250 PMCID: PMC8228322 DOI: 10.3390/ijms22126194] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2021] [Revised: 05/28/2021] [Accepted: 06/04/2021] [Indexed: 11/16/2022] Open
Abstract
Breast cancer (BC) is a leading cause of cancer deaths in women in less developed countries and the second leading cause of cancer death in women in the U.S. In this study, we report the inhibition of E2-mediated mammary tumorigenesis by Cuminum cyminum (cumin) administered via the diet as cumin powder, as well as dried ethanolic extract. Groups of female ACI rats were given either an AIN-93M diet or a diet supplemented with cumin powder (5% and 7.5%, w/w) or dried ethanolic cumin extract (1%, w/w), and then challenged with subcutaneous E2 silastic implants (1.2 cm; 9 mg). The first appearance of a palpable mammary tumor was significantly delayed by both the cumin powder and extract. At the end of the study, the tumor incidence was 96% in the control group, whereas only 55% and 45% animals had palpable tumors in the cumin powder and extract groups, respectively. Significant reductions in tumor volume (660 ± 122 vs. 138 ± 49 and 75 ± 46 mm3) and tumor multiplicity (4.21 ± 0.43 vs. 1.16 ± 0.26 and 0.9 ± 0.29 tumors/animal) were also observed by the cumin powder and cumin extract groups, respectively. The cumin powder diet intervention dose- and time-dependently offset E2-related pituitary growth, and reduced the levels of circulating prolactin and the levels of PCNA in the mammary tissues. Mechanistically, the cumin powder diet resulted in a significant reversal of E2-associated modulation in ERα, CYP1A1 and CYP1B1. Further, the cumin powder diet reversed the expression levels of miRNAs (miR-182, miR-375, miR-127 and miR-206) that were highly modulated by E2 treatment. We analyzed the composition of the extract by GC/MS and established cymene and cuminaldehyde as major components, and further detected no signs of gross or systemic toxicity. Thus, cumin bioactives can significantly delay and prevent E2-mediated mammary tumorigenesis in a safe and effective manner, and warrant continued efforts to develop these clinically translatable spice bioactives as chemopreventives and therapeutics against BC.
Collapse
|
5
|
Synthesis and anti-cancer activity of bis-amino-phosphine ligand and its ruthenium(II) complexes. Bioorg Med Chem Lett 2020; 30:127492. [DOI: 10.1016/j.bmcl.2020.127492] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2020] [Revised: 08/06/2020] [Accepted: 08/09/2020] [Indexed: 12/30/2022]
|
6
|
Anti-Cancer Potential of Cannabinoids, Terpenes, and Flavonoids Present in Cannabis. Cancers (Basel) 2020; 12:cancers12071985. [PMID: 32708138 PMCID: PMC7409346 DOI: 10.3390/cancers12071985] [Citation(s) in RCA: 93] [Impact Index Per Article: 23.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2020] [Revised: 07/17/2020] [Accepted: 07/19/2020] [Indexed: 02/06/2023] Open
Abstract
In recent years, and even more since its legalization in several jurisdictions, cannabis and the endocannabinoid system have received an increasing amount of interest related to their potential exploitation in clinical settings. Cannabinoids have been suggested and shown to be effective in the treatment of various conditions. In cancer, the endocannabinoid system is altered in numerous types of tumours and can relate to cancer prognosis and disease outcome. Additionally, cannabinoids display anticancer effects in several models by suppressing the proliferation, migration and/or invasion of cancer cells, as well as tumour angiogenesis. However, the therapeutic use of cannabinoids is currently limited to the treatment of symptoms and pain associated with chemotherapy, while their potential use as cytotoxic drugs in chemotherapy still requires validation in patients. Along with cannabinoids, cannabis contains several other compounds that have also been shown to exert anti-tumorigenic actions. The potential anti-cancer effects of cannabinoids, terpenes and flavonoids, present in cannabis, are explored in this literature review.
Collapse
|